Radioembolization with 90Y-Labelled Resin Microspheres in Patients with Liver Metastases from Neuroendocrine Tumors Abstract #1054

Introduction: Hepatic arterial embolization with 90Y-labelled microspheres is a method of delivering radioactivity to liver tumors, that has been used to treat primary hepatocellular carcinomas and liver metastases from colorectal carcinomas and neuroendocrine tumors.
Aim(s): To evaluate the efficacy and safety of radioembolization in patients with neuroendocrine tumors.
Materials and methods: 38 patients with progressing neuroendocrine liver metastases underwent 51 embolizations with 90Y-labelled resin microspheres (SIR-Spheres®). 31 embolizations were performed in the right, 11 in the left and 9 in both liver lobes. Mean activity was 1.3 GBq. Evaluation was performed with CT or MRI according to modified RECIST criteria.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Associate Prof Dan Granberg

To read results and conclusion, please login ...

Further abstracts you may be interested in

#182 Ki-67 (MIB-1) Proliferative Activity and Beta-Catenin Immunoexpression in Liver Metastases of Gastroenteropancreatic Neuroendocrine Tumors
Introduction: Assessment of liver metastases biology features associated with cell proliferation and adhesion has a strong prognostic impact in patients with gastroenteropancreatic (GEP) neuroendocrine carcinomas.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD, PhD Vera V. Delektorskaya
#457 Comparison of Transarterial Liver-Directed Therapies (LDT) for Low-Grade Metastatic Neuroendocrine Tumors (mNETs)
Introduction: Transarterial LDT can ameliorate symptoms and improve time to tumor progression (TTP) in mNETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Eric Engelman
#522 Effects of Transarterial Chemoembolization of Liver Metastases from Neuroendocrine Tumors on Clinical Outcome
Introduction: Trans-catheter arterial chemoembolization (TACE) is a method of treatment of non-resectable liver metastases from neuroendocrine tumors (NET) which provides control of clinical symptoms and tumor growth.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Sanja Ognjanovic
#530 Liver Transplantation for Metastatic Neuroendocrine Tumor: A Case Series and Proposed Selection Criteria
Introduction: Liver transplantation (LT) for neuroendocrine tumor (NET) metastases is associated with a high risk of tumor recurrence. Patient selection is the key to future success and its increased utilization.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Douglas Quan
Authors: Chan G, Kocha W, Reid R, Taqi A, ...
#541 Contrast-Enhanced Ultrasound (CEUS) is a Helpful Tool to Predict the Effectiveness of Somatostatin Analogues in Patients with Liver Metastases From Neuroendocrine Tumors
Introduction: Contrast-enhanced ultrasonography (CEUS) allows characterization of the micro-vascularization of tumor lesions. Liver metastases (LM) from neuroendocrine tumors (NET) show a typical pattern on CEUS, consistent with a rapid, intense and homogeneous enhancement (hypervascular pattern) in the arterial phase.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Valeria Ramundo
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team